Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
2.34 USD | -3.31% | -3.70% | -67.32% |
28/03 | CASI Pharmaceuticals, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023 | CI |
05/03 | Top Midday Gainers | MT |
Business Summary
Number of employees: 176
Sales per Business
USD in Million | 2022 | Weight | 2023 | Weight | Delta |
---|---|---|---|---|---|
Pharmaceutical Products
100.0
%
| 43 | 100.0 % | 34 | 100.0 % | -21.41% |
Sales per region
USD in Million | 2022 | Weight | 2023 | Weight | Delta |
---|---|---|---|---|---|
China
100.0
%
| 43 | 100.0 % | 34 | 100.0 % | -21.41% |
Managers
Managers | Title | Age | Since |
---|---|---|---|
Wei Wu He
CEO | Chief Executive Officer | 59 | 02/19/02 |
Wei Zhang
DFI | Director of Finance/CFO | 64 | 01/18/01 |
Chun Hua Wang
COO | Chief Operating Officer | 52 | 01/17/01 |
Chief Tech/Sci/R&D Officer | 65 | 01/17/01 | |
Wei Gao
LAW | General Counsel | 42 | 01/23/01 |
Kun Qian
AUD | Comptroller/Controller/Auditor | 42 | 01/22/01 |
Members of the board
Members of the board | Title | Age | Since |
---|---|---|---|
Wei Wu He
CEO | Chief Executive Officer | 59 | 02/19/02 |
Yue Wu
BRD | Director/Board Member | 62 | 01/13/01 |
Zhen Bo Su
BRD | Director/Board Member | 48 | 21/23/21 |
Thomas Folinsbee
BRD | Director/Board Member | 57 | 21/23/21 |
Xue Bo Zeng
BRD | Director/Board Member | 39 | 21/23/21 |
Share class
Vote | Quantity | Free-Float | Company-owned shares | Total Float | |
---|---|---|---|---|---|
Stock A | 1 | 13,813,327 | 7,042,899 ( 50.99 %) | 411,952 ( 2.982 %) | 50.99 % |
Company contact information
CASI Pharmaceuticals, Inc.
1701-1702, China Central Office Tower 1, No. 81 Jianguo Road
100025, Beijing
+
http://www.casipharmaceuticals.comSector
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-67.32% | 31.43M | |
+26.47% | 661B | |
+26.74% | 566B | |
-6.33% | 352B | |
+19.35% | 332B | |
+4.23% | 283B | |
+13.43% | 231B | |
+4.71% | 200B | |
-9.53% | 195B | |
-4.04% | 145B |
- Stock Market
- Equities
- CASI Stock
- Company CASI Pharmaceuticals, Inc.